Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it had accrued a total of 85 patients to the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo poor-risk acute myelogenous leukemia (AML).

Alan Kessman, Chief Executive Officer said, "We are extremely pleased to have reached this milestone in the pivotal Phase II trial of our lead anticancer agent. We will now proceed to analyze the data and, if warranted, prepare a New Drug Application for submission to the U.S. Food and Drug Administration in 2008." He added, "We continue to plan on the release of preliminary data from this trial at the American Society of Hematology (ASH) Meeting in December."

The pivotal Phase II trial, initiated in May 2006, is evaluating Cloretazine(R) (VNP40101M) as a single agent in previously untreated AML patients over the age of 60 with de novo poor-risk AML. Patients are eligible for this trial if they are at least 60 years of age with de novo AML and have one of the following additional risk factors: (i) unfavorable cytogenetics; (ii) an ECOG performance status of 2 or greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 with de novo AML who do not have favorable cytogenetics are also eligible.

The primary endpoint for this trial is the complete response rate (including complete remission (CR) and complete remission with incomplete platelet recovery (CRp)). Secondary endpoints include overall survival, disease-free survival and progression-free survival.

The trial ha
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 Today, Rhodes Pharmaceuticals L.P. announced that ... indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) ... The announcement comes just one ... U.S. Food and Drug Administration (FDA). ... methylphenidate capsule with an onset of effect of ...
(Date:5/21/2015)... 2015 Research and ... addition of the "North American Joint ... Replacement, Elbow Replacement, Hip Replacement, Knee Replacement, ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... valued at $4,470.9 million in 2014 and ...
(Date:5/21/2015)... ATLANTA , May 21, 2015  CryoLife, Inc. ... tissue processing company focused on cardiac and vascular surgery, ... a quarterly cash dividend for the second quarter 2015 ... quarterly cash dividend of $0.03 per share will be ... of record as of June 12, 2015.  The ex-dividend ...
Breaking Medicine Technology:Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2
... inception in 2007, the world’s leading medical technology ... this year’s conference was no exception. Compared with ... up nearly 12 percent, CEO-level participation rose five ... fifth annual conference also drew attendees from 22 ...
... Oct. 5, 2011 myMatrixx®, a full-service pharmacy and ... today that Phil Walls, R.Ph., Chief Clinical & Compliance ... awards programs. The first is Health Care Heroes hosted ... is a finalist in the Medical Professional Non-Physician category. ...
Cached Medicine Technology:Annual AdvaMed MedTech Conference Continues Impressive Growth 2Annual AdvaMed MedTech Conference Continues Impressive Growth 3myMatrixx's Phil Walls, R.Ph. Receives National and Regional Recognition 2
(Date:5/23/2015)... Injury lawyer Steven H. Heisler commented today on ... Maryland legislature but which has not been signed to date ... HB 449 with overwhelming bipartisan support on April 10, ... law. This bill ensures that fracking is prohibited in Maryland ... danger of fracking to our water supplies and the air ...
(Date:5/22/2015)... San Francisco, CA (PRWEB) May 22, 2015 ... is hosting two exciting events in June. They will ... First Professional Doctorate and a two-day class on Classical ... 1:30-2:30 p.m. June 3, Dr. Steve Given, the Dean ... he will discuss the new First Professional Doctorate program. ...
(Date:5/22/2015)... York, New York (PRWEB) May 22, 2015 ... http://www.xareltolawsuit2015.com/ ) filed on behalf of individuals who ... due to its use continue to move forward ... Louisiana. According to a Pretrial Order dated May ... the preservation of documents and electronically stored information. ...
(Date:5/22/2015)... 22, 2015 Combination therapy, or ... for chronic obstructive pulmonary disorder (COPD) as the ... AstraZeneca plc as well as Germany’s Boehringer Ingelheim ... position. But will market payers, clinicians and patients ... products to completely new ones? , In spite ...
(Date:5/22/2015)... Family, friends, students, colleagues, mentors and fellow physicians ... D. Leffall, on Monday, May 18, with an 85th ... in the hospital’s Tower Auditorium. Leffall’s younger sister, 83-year-old ... to keep the secret. “I’d like to go in ... know something is up,” she said. , After more ...
Breaking Medicine News(10 mins):Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:ACTCM Announces Upcoming June Events 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2
... fifth largest journal publisher, is proud to be participating ... Development launched today by the Council of Science Editors. ... awareness and stimulate interest and debate on the crucial ... journals from both developed and developing countries will simultaneously ...
... IL, October 22, 2007) Hospitalized patients who smoke ... use of hypnotherapy than patients using other smoking cessation ... 73rd annual international scientific assembly of the American College ... participated in one hypnotherapy session were more likely to ...
... Lawrence, UCLA,s chief of vascular surgery, picks up size 7 crochet ... scarves but to use in a new technique he has developed ... of the new outpatient procedure, called light-assisted stab phlebectomy, or LASP, ... The American Surgeon. , More than 250 ...
... PITTSBURGH, Oct. 22 InformationWeek magazine, one of,the ... 62nd in its annual ranking of the top ... ranked second in the health insurance field and,fourth ... the rankings from,170th last year. Tom Tabor, ...
... 31, 2007 Win: Cash prize of $1000 ... Immunology (AAAAI), the,largest professional medical specialty organization in ... allied,health professionals and others with a special interest ... now accepting entries for the 2007 Annual,Samter Journalism ...
... all the difference, report finds , , MONDAY, Oct. 22 ... saved by a coordinated global effort to improve nutrition ... fuels in underdeveloped countries, a new study finds. , ... of almost 1.5 million children in sub-Saharan Africa, 800,000 ...
Cached Medicine News:Health News:9 SAGE journals participate in global theme issue on poverty and human development 2Health News:Hypnosis for smoking cessation sees strong results 2Health News:UCLA doctor develops new technique to treat varicose veins 2Health News:UCLA doctor develops new technique to treat varicose veins 3Health News:National Magazine Ranks Highmark 62nd Among Nation's 500 Most Innovative Users of Information Technology 2Health News:Call for Entries: 2007 AAAAI Annual Samter Journalism Awards 2Health News:Saving Millions of Children's Lives Is Possible 2
... BacT/Alert 3D Signature is a state ... system that integrates blood, sterile body ... a powerful microbiology workstation with comprehensive ... volume identification and where expanded flexibility ...
... 3D Select is a state ... detection system that integrates blood, ... culturing. This system is useful ... laboratory information system (LIS) connectivity ...
The Vitek 2 - XL is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat ...
IDS Rapid ANA II System, a microbial identification system....
Medicine Products: